<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">Cerebral ischaemia</z:e> is a leading cause of <z:hpo ids='HP_0011420'>death</z:hpo> and disability </plain></SENT>
<SENT sid="1" pm="."><plain>The objective of the present investigation was to explore the neuroprotective potentials of <z:chebi fb="0" ids="3347">candesartan</z:chebi> and <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> alone and their combination against the <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> induced behavioral, biochemical, and <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> dysfunction </plain></SENT>
<SENT sid="2" pm="."><plain>Male Wistar rats (200-220 g) were subjected to bilateral common carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> for 30 min followed by 24 h reperfusion </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="3347">Candesartan</z:chebi> (0.1 and 0.3 mg/kg) and <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> (10 and 20 mg/kg) were pretreated for 7 days before animals were subjected to <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> reperfusion injury </plain></SENT>
<SENT sid="4" pm="."><plain>Various behavioral tests (locomotor activity and rotarod performance), biochemical parameters (Malondialdehyde levels, <z:chebi fb="95" ids="16301">nitrite</z:chebi> concentration, <z:chebi fb="1" ids="18421">superoxide</z:chebi> dismutase and catalase activity, redox ratio, and GST) and <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> enzyme (Complex I, II, III, and IV) dysfunctions were measured in cerebral cortex, striatum and hippocampus of the ischaemic brain </plain></SENT>
<SENT sid="5" pm="."><plain>Seven days <z:chebi fb="0" ids="3347">candesartan</z:chebi> (0.1 and 0.3 mg/kg) or <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> (10 and 20 mg/kg) pretreatment significantly attenuated neurobehavioral alterations, oxidative damage and restored <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> enzyme dysfunction as compared to control (I/R) group </plain></SENT>
<SENT sid="6" pm="."><plain>Further, combined treatment of <z:chebi fb="0" ids="3347">candesartan</z:chebi> (0.1 mg/kg) and <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> (10 mg/kg) significantly potentiated their protective effect which was significant as compared to their effect alone </plain></SENT>
<SENT sid="7" pm="."><plain>Present study suggests the protective effect of <z:chebi fb="0" ids="3347">candesartan</z:chebi> and <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> and their combination against <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> reperfusion induced behavioral and biochemical alterations in rats </plain></SENT>
</text></document>